Evidence map›Paper›PMID 24014682›Full record

ArticleStem cells translational medicine2013

Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use.

Margarita Gutova, Joseph A Frank, Massimo D'Apuzzo, Vazgen Khankaldyyan, Megan M Gilchrist, Alexander J Annala, Marianne Z Metz, Yelena Abramyants, Kelsey A Herrmann, Lucy Y Ghoda and 8 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Intravenously Infused Stem Cells for Cancer Treatment.Stem cell reviews and reports · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.Frontiers in bioengineering and biotechnology · 2020
    Review
  15. Seeing Better and Going Deeper in Cancer Nanotheranostics.International journal of molecular sciences · 2019
    Review
  16. Article
  17. Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Margarita GutovaDepartments of Neurosciences.
Joseph A Frank
Massimo D'Apuzzo
Vazgen Khankaldyyan
Megan M Gilchrist
Alexander J Annala
Marianne Z Metz
Yelena Abramyants
Kelsey A Herrmann
Lucy Y Ghoda
Joseph Najbauer
Christine E Brown
M Suzette Blanchard
Maciej S Lesniak
Seung U Kim
Michael E Barish
Karen S Aboody
Rex A Moats
City Of Hope National Medical Center · USUniversity of Southern California · USNational Institutes of Health · USUniversity of British Columbia · CAUniversity of Chicago · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Neural Stem Cell Based Virotherapy for Malignant GliomaU01NS069997 · NINDS · UNIVERSITY OF CHICAGO · PI YAMINI, BAKHTIAR · 2010 to 2014
$6.1M
Pre-clinical evaluation of Magnetically labeled Cells for Cellular MRIZIACL090007 · CLC · CLINICAL CENTER · PI FRANK, JOSEPH · 2009 to 2018
$0k
NCI NIH HHS P30 CA033572NCI NIH HHS P30-CA033572NINDS NIH HHS U01 NS069997
6 · The paper itself

Abstract

Numerous stem cell-based therapies are currently under clinical investigation, including the use of neural stem cells (NSCs) as delivery vehicles to target therapeutic agents to invasive brain tumors. The ability to monitor the time course, migration, and distribution of stem cells following transplantation into patients would provide critical information for optimizing treatment regimens. No effective cell-tracking methodology has yet garnered clinical acceptance. A highly promising noninvasive method for monitoring NSCs and potentially other cell types in vivo involves preloading them with ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) to enable cell tracking using magnetic resonance imaging (MRI). We report here the preclinical studies that led to U.S. Food and Drug Administration approval for first-in-human investigational use of ferumoxytol to label NSCs prior to transplantation into brain tumor patients, followed by surveillance serial MRI. A combination of heparin, protamine sulfate, and ferumoxytol (HPF) was used to label the NSCs. HPF labeling did not affect cell viability, growth kinetics, or tumor tropism in vitro, and it enabled MRI visualization of NSC distribution within orthotopic glioma xenografts. MRI revealed dynamic in vivo NSC distribution at multiple time points following intracerebral or intravenous injection into glioma-bearing mice that correlated with histological analysis. Preclinical safety/toxicity studies of intracerebrally administered HPF-labeled NSCs in mice were also performed, and they showed no significant clinical or behavioral changes, no neuronal or systemic toxicities, and no abnormal accumulation of iron in the liver or spleen. These studies support the clinical use of ferumoxytol labeling of cells for post-transplant MRI visualization and tracking.

Indexed as

Ferrosoferric OxideAnimalsCell TrackingHumansImmunohistochemistryMagnetic Resonance ImagingMiceNeural Stem CellsStaining and LabelingStem Cell TransplantationFerrosoferric OxideCell transplantationCellular therapyClinical trialsIn vivo trackingNeural stem cellStem cellStem cell transplantation

Identifiers

PMID24014682
PMCPMC3785261
OpenAlexW2021912058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.